Lilly/BI’s Jardiance Is First Diabetes Drug To Show A CV Benefit – Now What?
This article was originally published in The Pink Sheet Daily
Executive Summary
The SGLT2 inhibitor demonstrated superiority in a 7,000-patient cardiovascular outcomes trial. The implications for the class of drugs – and the broader diabetes treatment market – could be substantial.
You may also be interested in...
FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change
FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.